Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915957 | 0.91 | SLC9A1 (0.46) | SLC9A1HCAR3PKMCNR2CNR1 | |
| SCHEMBL19915940 | 0.89 | PKM (0.46) | SLC9A1HCAR3PKMCNR2MAPT | |
| SCHEMBL19848183 | 0.85 | HCAR3 (0.58) | SLC9A1HCAR3PKMCNR2MAPT | |
| SCHEMBL19911623 | 0.84 | SLC9A1 (0.49) | SLC9A1HCAR3ICMTGRM2 | |
| SCHEMBL19911486 | 0.83 | SLC9A1 (0.50) | SLC9A1HCAR3MAPT | |
| SCHEMBL19848725 | 0.82 | PKM (0.56) | SLC9A1HCAR3PKMMAPTKCNMA1 | |
| SCHEMBL19911591 | 0.82 | SLC9A1 (0.49) | SLC9A1HCAR3MAPT | |
| SCHEMBL19915956 | 0.80 | SLC9A1 (0.41) | SLC9A1HCAR3PKMMAPTICMT | |
| SCHEMBL19911517 | 0.80 | SLC9A1 (0.47) | SLC9A1HCAR3MAPT | |
| SCHEMBL19915920 | 0.79 | CNR2 (0.43) | CNR2MAPTCNR1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885PKM 2292/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885PKM 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.